Offer people with chronic pain that drugs and surgery haven't fixed a lasting, opioid-sparing alternative, and widen spinal cord stimulation to diabetic nerve pain and back pain without surgery.
Sold by Globus since the April 2025 Nevro deal; Q2 2026 sales fell 14% as trial implants stayed low.
Updated 6 Aug 2026Checked 11 Oct0 updates this week
Thin leads are slid into the space just outside the spinal cord's covering and wired to a rechargeable pulse generator under the skin.
Older stimulators mask pain with a tingling buzz at under 1,200 Hz. At 10 kHz the pulses quiet pain signals without that sensation.
AdaptivAI asks patients how they feel via an app and uses data from 100,000+ patients to adjust settings, aiming for better relief with fewer clinic visits.
| Spec | Nevro HFX (10 kHz spinal cord stimulation) | Senza / HFX iQ | Change |
|---|---|---|---|
| Stimulation frequency | 10 kHzR (reported) | 2-1,200 Hz (traditional SCS) | ▲ 9,998 Hz |
| Responders at 3 months (SENZA-RCT) | 75% (50%+ pain cut)R (reported) | — | —no comparable change |
| Avg pain relief, diabetic neuropathy | 76% at 6 monthsR (reported) | — | —no comparable change |
| Recharges needed | As few as 6 per yearR (reported) | — | —no comparable change |
| Data behind AdaptivAI | 100M+ data points, 100,000+ patientsR (reported) | — | —no comparable change |
| Nevro revenue, 2024 (preliminary) | $408-409MR (reported) | — | —no comparable change |
R reported by the company
Globus Medical
ExcelsiusGPS surgical navigation, spine robotics
Globus Medical makes musculoskeletal devices and the ExcelsiusGPS robotic navigation platform for spine and orthopedic surgery. NYSE-listed (GMED) since 2009.
globusmedical.com (opens globusmedical.com)Company profile →
